Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Amira Barkal(Stanford University), Kipp Weiskopf(Brigham and Women's Hospital), Kevin S. Kao(Stanford University), Sydney Gordon(Stanford University), Benyamin Rosental(Stanford University), Ying Ying Yiu(Stanford University), Benson M. George(Stanford University), Maxim Markovic(Stanford University), Nan Ring(Stanford University), Jonathan M. Tsai(Stanford University), Kelly M. McKenna(Stanford University), Po Y. Ho(Stanford University), Robin Z. Cheng(Stanford University), James Y. Chen(Stanford University), Layla J. Barkal(University of Wisconsin–Madison), Aaron M. Ring(Yale University), Irving L. Weissman(California Institute for Regenerative Medicine), Roy L. Maute(California Institute for Regenerative Medicine)
Cited by 555Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis